Avelumab (anti-PD-L1)

Catalog No.A2015 Synonyms: Bavencio, MSB0010718C

For research use only.
Not for use in humans.

Avelumab (anti-PD-L1) (Bavencio, MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.

Quality Control

Choose Selective PD-1/PD-L1 Inhibitors

Biological Activity

Description Avelumab (anti-PD-L1) (Bavencio, MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.
In vitro

Co-incubating chordoma cells with brachyury-specific CD8+ T cells results in significant upregulation of PD-L1 on the tumor cells, mediated by the CD8+ T cells' IFN-γ production, and increases sensitivity of chordoma cells to avelumab-mediated ADCC. Residential cancer stem cell subpopulations of chordoma cells are also killed by avelumab-mediated ADCC to the same degree as non-cancer stem cell populations. As a monotherapy for chordoma, avelumab may enable endogenous NK cells, while in combination with T-cell immunotherapy, such as a vaccine, avelumab may enhance NK-cell killing of chordoma cells via ADCC.[1]

In vivo

An aggressive, bioluminescent orthotopic bladder cancer model, MB49 tumor cells transfected with luciferase (MB49luc) is used to study the antitumor effects of avelumab. MB49luc bladder tumors are highly positive for the expression of PD-L1 and avelumab administration induces significant (P<0.05) antitumor effects.[2]

Protocol

Cell Research:
- Collapse
  • Objective: Antibody-dependent cellular cytotoxicity assay
    Cells: UM-Chor1 cells
    Concentrations: 2 μg/mL
    Incubation Time: 30 min
    Method: To examine the relationship between a CSC subpopulation and ADCC activity, UM-Chor1 cells are left untreated or treated with 50 ng/mL of IFN-γ for 24 h. Cells are then plated as targets at 50,000 cells/well in 6-well round-bottom culture plates and incubated with 2 μg/mL of avelumab at room temperature for 30 min. NK cells are added at 2500,000 cells/well at an E:T ratio of 50:1. After 4 h, tumor cells are harvested and stained with antibodies for flow cytometry.
    Reference: https://pubmed.ncbi.nlm.nih.gov/27172898

    Avelumab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

Animal Research:
- Collapse
  • Objective: Measurement of individual tumors
    Animal Models: 16- to 18-week-old female C57BL/6 mice
    Formulation: DPBS
    Dosages: 400 μg/100 μL
    Administration: i.p.
    Reference: https://pubmed.ncbi.nlm.nih.gov/26921031/

    Avelumab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

Product Details

CAS No. 1537032-82-8
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source Human
Storage Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy Avelumab (anti-PD-L1) | Avelumab (anti-PD-L1) supplier | purchase Avelumab (anti-PD-L1) | Avelumab (anti-PD-L1) cost | Avelumab (anti-PD-L1) manufacturer | order Avelumab (anti-PD-L1) | Avelumab (anti-PD-L1) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID